Clinical Trials Logo

Clinical Trial Summary

Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment to remove clot within 12 hours following stroke onset. Neu2000KWL will be administered before endovascular treatment.


Clinical Trial Description

Neu2000 was designed as a multi-target neuroprotectant preventing both the NMDA receptor, a Ca2+ -permeable glutamate receptor, and free radicals, two major routes of brain cell death in stroke. Neu2000 is a moderate NR2B-selective NMDA receptor antagonist and spin trapping molecule (=free radical scavenger or antioxidant). Therapeutic potential of Neu2000 has been well demonstrated in four animal models of stroke with better efficacy and therapeutic time windows than either NMDA receptor antagonist or anti-oxidant advanced to clinical trials. In human phase I studies of 165 healthy subjects conducted in the United States and China, Neu2000KWL showed promising safety profiles without any serious adverse events up to a single intravenous infusion of 6000 mg that is far beyond the therapeutic target dose determined in animal models of transient ischemic stroke. Very recently, acute endovascular recanalization therapy has been introduced as the new standard care of care in acute ischemic stroke. The present study is aimed to examine efficacy and safety of Neu2000KWL in acute ischemic stroke patients receiving endovascular thrombectomy within 12 hours of stroke onset. This is a randomized trial, with placebo comparison, of comparing functional outcome at week 12 after 10 times of administration for five days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05041010
Study type Interventional
Source GNT Pharma
Contact Chun San An
Phone 82-31-8005-9910
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date September 2021
Completion date January 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT04129125 - The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System N/A
Enrolling by invitation NCT05024292 - Oriental Research AlliaNce of Acute Ischemic Stroke Given Endovascular Treatment
Not yet recruiting NCT05048004 - Cerebral Embolization During Pulmonary Vein Isolation
Not yet recruiting NCT05004233 - Transmission Electron Microscopy Images for Platelet Ultrastructural Criteria Before and After the Onset of an Antiplatelet Agent N/A
Not yet recruiting NCT05008588 - Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Sub-Acute Stroke Infarct Phase 1/Phase 2
Not yet recruiting NCT05044507 - The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study N/A
Not yet recruiting NCT03684564 - RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome Phase 2/Phase 3
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Terminated NCT01852201 - POSITIVE Stroke Clinical Trial N/A
Not yet recruiting NCT01923818 - Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events Phase 2/Phase 3